Skip to content

Independent medical information for international patients

Menu

Medical news

Each update carries a summary written by WellCareChina with AI assistance, the source name, the date, and a link to the original.

  • An operating theatre with a fluorescence imaging tower and a specimen tray.

    AI-assisted summary

    Phase 2 study tests an imaging probe that lights up bladder tumours

      Published Source: ClinicalTrials.gov (NLM/NIH)

      Yunnan Cancer Hospital has registered a phase 2 study, first posted on 30 September 2026, of a Trop2-targeted near-infrared (NIR-II) fluorescent probe applied to bladder specimens removed during surgery. The record notes that standard white-light cystoscopy can miss up to 30% of non-muscle-invasive bladder tumours, and that the study will compare the probe’s readings with […]

    • A rack of vials lifted from a cryogenic freezer.

      AI-assisted summary

      Phase 1 trial of in vivo CAR-T therapy for relapsed AML registered in Beijing

      Published Source: ClinicalTrials.gov (NLM/NIH)

      A study registered on ClinicalTrials.gov on 25 September 2026 plans to test an in vivo CAR-T therapy targeting CLL-1 in up to 12 adults with relapsed or refractory acute myeloid leukaemia at the Chinese PLA General Hospital in Beijing. The record describes a single-arm phase 1 dose-escalation design, lists an estimated start date of 30 […]

    • A chest CT scan on a lightbox in a clinic.

      AI-assisted summary

      Phase 2 lung cancer trial with Chinese sites is recruiting

        Published Source: ClinicalTrials.gov (NLM/NIH)

        A phase 2 study registered on ClinicalTrials.gov and updated on 25 September 2026 is recruiting about 130 patients with non-small cell lung cancer to test an investigational drug given with chemoradiation followed by consolidation immunotherapy. The listed sites include hospitals in Dongguan, Guangzhou and Jinan. The sponsor is Johnson & Johnson Enterprise Innovation Inc. Registry […]

      • A blood collection tube beside a benchtop DNA sequencer.

        AI-assisted summary

        Trial uses blood ctDNA to steer immunotherapy before colon cancer surgery

          Published Source: ClinicalTrials.gov (NLM/NIH)

          Fudan University Shanghai Cancer Center has registered a phase 2 study, first posted on 25 September 2026, that uses repeated blood tests for circulating tumour DNA (ctDNA) to guide immunotherapy given before surgery in patients with dMMR/MSI-H colon cancer. According to the record, participants whose ctDNA clears go on to surgery, while those whose ctDNA […]

        • A petri dish examined in a laboratory.

          AI-assisted summary

          Chinese teams publish phase 1 gene therapy results in adolescents with haemophilia B

          Published Source: Chinese Academy of Medical Sciences

          The Chinese Academy of Medical Sciences said on 24 September 2026 that teams from its Institute of Hematology, Tongji Hospital and a biotechnology company published a phase 1 trial of an AAV gene therapy in adolescents with haemophilia B in Nature Medicine. The academy’s account describes the results as preliminary evidence for this age group. […]

        • Shelves of goods in a warehouse.

          AI-assisted summary

          Guangdong runs a cross-border exercise for its Hong Kong-Macao drug and device scheme

          Published Source: Guangdong Medical Products Administration

          The Guangdong Medical Products Administration said it held an exercise in Nansha on 23 September 2026 testing emergency response for the scheme that lets designated mainland hospitals in the Greater Bay Area use drugs and medical devices approved in Hong Kong or Macao. The administration said the scheme has covered 71 designated institutions, 178 products […]

        • An endoscope tower and a coiled endoscope in a procedure room.

          AI-assisted summary

          Phase 2 colorectal cancer trial opens at Guangdong Provincial People’s Hospital

            Published Source: ClinicalTrials.gov (NLM/NIH)

            A phase 2 study registered on ClinicalTrials.gov and last updated on 24 September 2026 is recruiting about 160 patients with refractory RAS wild-type metastatic colorectal cancer. The record names Guangdong Provincial People’s Hospital in Guangzhou as the sponsor and site and lists bevacizumab, sintilimab, cetuximab and irinotecan; the stated primary endpoint is objective response rate. […]

          • Gloved hands pipetting into a multi-well culture plate.

            AI-assisted summary

            Phase 3 trial of an autologous cell therapy for COPD registered at a Guangzhou hospital

            Published Source: ClinicalTrials.gov (NLM/NIH)

            A study registered on ClinicalTrials.gov and last updated on 24 September 2026 plans to test an autologous cell therapy, REGEND001, made from airway basal stem cells, in about 102 adults with chronic obstructive pulmonary disease and emphysema. The record describes a multicentre, randomised, blinded, placebo-controlled phase 3 trial at The First Affiliated Hospital of Guangzhou […]

          • Dried herbs used in traditional Chinese medicine.

            AI-assisted summary

            China’s traditional medicine regulator reviews digital projects

            Published Source: National Administration of Traditional Chinese Medicine

            The National Administration of Traditional Chinese Medicine said it held a meeting in Chongqing on 20-21 September 2026 with the National Data Administration and other organisations on digital projects in traditional Chinese medicine, including data pilot zones. The administration said it would set out a digital roadmap intended to improve access to traditional medicine services. […]

          • A person wearing a wireless EEG headband.

            AI-assisted summary

            China issues a standard for AI-powered brain-computer interface devices

            Published Source: CGTN

            CGTN reported on 14 September 2026 that China’s National Medical Products Administration issued what the regulator describes as the world’s first product standard for brain-computer interface medical devices that use artificial intelligence to process EEG data. The standard sets requirements for data collection, processing, annotation, storage and access, and takes effect on 1 September 2027.